Targeting Androgen Receptor-HSP27 Signaling in Glioblastoma

胶质母细胞瘤中靶向雄激素受体 HSP27 信号传导

基本信息

  • 批准号:
    10201212
  • 负责人:
  • 金额:
    $ 44.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-01 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

Abstract Glioblastoma (GBM) is the most malignant brain tumor with poor prognosis. Very few patients could survive more than a year after the diagnosis even with the development of new surgical techniques, which is primarily due to the highly infiltrative/invasive behavior of these tumors. GBM commonly has de novo or acquired resistance to Temozolomide (TMZ), a DNA-alkylating reagent that is the only chemotherapy for GBM. GBM has a higher rate in men than women. Androgen Receptor (AR) overexpressing contributes to this sex difference of GBM. AR is a client protein of the 27 kDa Heat Shock Protein (HSP27) that is an anti- apoptotic chaperone overexpressed in GBM. HSP27 promote the biological activity of AR, which contributes to GBM progression. We hypothesize that HSP27-AR axis is a critical driving force to tumor growth in GBM, particularly for the male GBM patients. The proposed studies arise from our efforts to develop small molecule HSP27 inhibitor to induce AR degradation in GBM, which is a new approach for the treatment of GBM. We have identified a small molecule HSP27 inhibitor, and it greatly induced AR degradation and selectively inhibited AR overexpressed GBM cell growth. Furthermore, we have a preliminary structure activity relationship summarized for the designing of next generation of derivatives to optimize the lead compound. We have also demonstrated that targeting HSP27-AR is selective to AR overexpressed GBM cells. We propose to systematically investigate the in vivo activity of the drug candidate and its combination with TMZ in GBM models, and further structurally optimize the lead compound. Aim 1. Lead optimization of HSP27 inhibitors as AR abolisher in GBM. We will lead optimize the structure of lead compound, by a mix of rationale design, synthesis and screening. We will then: a) Examine the growth of GBM cells in the presence of these derivatives to summarize a structure activity relationship (SAR) for growth inhibition. We will also exclude toxic compounds by testing with non-malignant cells. b) Determine the HSP27 targeting effect of top derivatives with in vitro assays including HSP27 chaperone assay, surface plasmon resonance (SPR) HSP27 assay and cellular AR protein level determination. c) Test the LogP value of the compounds, and determine the blood brain barrier passing effect of the compounds with LC-MS/MS method. Aim 2. In vivo investigation of the drug candidates with GBM patient derived xenograft (PDX) tumor models. We will test the lead compound and newly identified ones with in vivo GBM PDX model, including subcutaneous PDX and intracranial PDX GBM models, and the AR level in the tumor as a therapeutic biomarker will be examined. TMZ will be the positive control and vehicle as the negative control. Another experiment will be the drug candidate combination with TMZ.
摘要

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bin Su其他文献

Bin Su的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bin Su', 18)}}的其他基金

Drug development of orally active anti-trypanosomiasis agents
口服活性抗锥虫病药物的药物开发
  • 批准号:
    8434287
  • 财政年份:
    2013
  • 资助金额:
    $ 44.55万
  • 项目类别:

相似海外基金

Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
  • 批准号:
    DP240100640
  • 财政年份:
    2024
  • 资助金额:
    $ 44.55万
  • 项目类别:
    Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
  • 批准号:
    23K01889
  • 财政年份:
    2023
  • 资助金额:
    $ 44.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
  • 批准号:
    10452217
  • 财政年份:
    2022
  • 资助金额:
    $ 44.55万
  • 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
  • 批准号:
    10670838
  • 财政年份:
    2022
  • 资助金额:
    $ 44.55万
  • 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
  • 批准号:
    DP200100492
  • 财政年份:
    2020
  • 资助金额:
    $ 44.55万
  • 项目类别:
    Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
  • 批准号:
    407264
  • 财政年份:
    2019
  • 资助金额:
    $ 44.55万
  • 项目类别:
    Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
  • 批准号:
    18K18240
  • 财政年份:
    2018
  • 资助金额:
    $ 44.55万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
  • 批准号:
    17K12379
  • 财政年份:
    2017
  • 资助金额:
    $ 44.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
  • 批准号:
    17K13937
  • 财政年份:
    2017
  • 资助金额:
    $ 44.55万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
  • 批准号:
    8742767
  • 财政年份:
    2014
  • 资助金额:
    $ 44.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了